Mental Health and PMS: Anxiety, Depression, and the Cycle

Introduction

Mental health and the menstrual cycle are deeply intertwined. Hormonal fluctuations across the cycle influence mood, cognition, anxiety, and vulnerability to depressive episodes. Conversely, pre-existing mental health conditions affect how the cycle is experienced. For women who live with both PMS and a mental health condition, understanding these interactions is crucial for effective management.

The Cycle-Mood Connection

The menstrual cycle modulates key neurotransmitter systems that regulate mood:

• Estrogen enhances serotonin
• dopamine
• and noradrenaline signalling — contributing to the relatively positive mood many women experience in the follicular phase.
• Progesterone (via allopregnanolone) modulates GABA receptors — generally calming but paradoxically anxiogenic in women with PMS/PMDD.
• Falling estrogen in the late luteal phase and around menstruation reduces serotonergic tone — contributing to low mood
• irritability
• and anxiety.
• The HPA axis is modulated by ovarian hormones — estrogen generally reduces cortisol
• progesterone has cortisol-like effects at the glucocorticoid receptor.

PMS vs Premenstrual Exacerbation of Existing Conditions

It is essential to distinguish true PMS/PMDD (where symptoms are essentially absent in the follicular phase) from premenstrual exacerbation of underlying conditions. Studies show that depression, bipolar disorder, anxiety disorders, OCD, eating disorders, schizophrenia, and migraine can all worsen premenstrually — without meeting PMDD criteria.

Women with major depressive disorder often report that their mood is generally low throughout the cycle but becomes noticeably worse in the 1–2 weeks before their period. This is premenstrual exacerbation of depression, not PMDD. The treatment priority is the underlying depression; addressing PMS symptoms on top of this is secondary.

Anxiety and the Luteal Phase

Luteal-phase anxiety can be severe. As explained in previous articles, progesterone\'s metabolite allopregnanolone paradoxically activates excitatory GABA-A receptor configurations in susceptible women, driving anxiety, tension, and panic-like symptoms. Women with pre-existing generalised anxiety disorder or panic disorder are particularly vulnerable to luteal-phase worsening.

Practical implications: Women should flag their cycle phase to their mental health provider, as medication adjustments, session timing, and coping strategies may need to account for predictable premenstrual worsening.

Depression in the Luteal Phase

PMDD is classified as a depressive disorder in the DSM-5 — a recognition that premenstrual mood dysregulation of sufficient severity represents a distinct, biologically driven mood disorder. But even below the threshold of PMDD, many women experience subclinical depressive symptoms (low mood, hopelessness, reduced interest) in the late luteal phase.

Self-compassion and realistic expectations are important: knowing that these feelings are hormonally driven, time-limited, and will resolve with menstruation helps women resist catastrophising ("I always feel like this" / "nothing will ever get better"). CBT specifically targets these cognitive distortions.

Mindfulness and Self-Compassion

Mindfulness-based approaches — mindfulness-based stress reduction (MBSR

When to Seek Professional Help

Mental health support should be sought if:

• Emotional PMS symptoms significantly impair relationships
• work
• or daily function
• Premenstrual mood symptoms include thoughts of self-harm or suicide
• Symptoms persist beyond menstruation or occur outside the luteal phase
• A prior diagnosis of depression
• bipolar
• or anxiety disorder is worsening premenstrually
• Over-the-counter or lifestyle approaches have not provided adequate relief after 3 months

Treatment Options

• SSRIs: First-line for PMDD (sertraline
• fluoxetine
• paroxetine) — continuous or luteal-phase dosing
• CBT: Strong evidence for PMS/PMDD; addresses cognitive distortions and builds coping skills
• Combined oral contraceptives: Can stabilise hormones and reduce mood fluctuations
• GnRH analogues: For severe refractory PMDD — suppresses ovarian cycling (short-term with add-back HRT)
• Psychoeducation: Simply understanding the hormonal basis of symptoms reduces distress for many women

References: DSM-5 PMDD criteria; ACOG 2023; Eisenlohr-Moul T, Current Psychiatry Reports 2019; Pearlstein T, Steiner M, J Clin Psychiatry 2008.